Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
The first doses of Advaxis‘ axalimogene filolisbac, or AXAL, have been administered to women with advanced cervical cancer in a Phase 3 trial of the treatment’s effectiveness after chemotherapy and radiation. The ... Read more
Women with moderate-to-severe changes in their cervical cells who don’t get follow-up testing or treatment are four times more likely to develop cervical cancer than women who receive treatment, ... Read more
CEL-SCI’s Phase 3 clinical trial assessing its investigational drug Multikine in patients with squamous cell carcinoma of the head and neck (SCCHN) recently was placed on partial clinical hold ... Read more
Standard of care for locally advanced cervical cancer includes external radiation, chemotherapy, and a form of internal radiation called brachytherapy. But results from a large study show that more ... Read more
Human papilloma virus (HPV)-associated head and neck cancers are on the increase, particularly in young white men. Recently, researchers have revealed that oral HPV infection is influenced by lifestyle choices, such as smoking ... Read more
Patients with persistent or recurrent metastatic carcinoma of the cervix (PRmCC) may strongly benefit from treatment with Advaxis‘ experimental vaccine axalimogene filolisbac (AXAL), according to preliminary data from the ... Read more